Community pharmacy is at the heart of one of the most ambitious clinical trials ever undertaken by the UK's primary care network, says senior academic pharmacist
Professor Mahendra Patel.
The PANORAMIC trial has been designed to rapidly evaluate several antiviral treatments over time that could help people at high risk of Covid-19 recover sooner,
prevent the need for hospital admission and so ease the burden on the NHS.
The Platform Adaptive trial of NOvel antiviRals for eArly treatMent of Covid-19 In the Community (PANORAMIC) is a national priority trial led by Oxford University's
Primary Care Clinical Trials Unit.
Lead investigators say the study will enable early and rapid testing of novel antiviral agents and help repurpose existing drugs against Covid-19. As soon as the trial is set up for delivery, it will be open to eligible participants from across the UK.
Prof Patel, a key member of the trial's core team, said: "I'm really excited with this news and also by the prospect that there is a huge potential for pharmacy teams to help play a vital role in supporting this highly ambitious trial, as they have with the PRINCIPLE trial, now the world's largest community based clinical trial for Covid19."
The Pharmacists' Defence Association has asked Boots UK to waive any restrictive clause that prevents pharmacists working with the multiple from working for other pharmacy employers, even after leaving the company.
However, the firm is yet to respond to the formal request, PDA said in an update.
This request follows demand from the association members shortly after the company announced it's plans to cut opening hours.
On workforce shortages, the PDA stated if there was a genuine shortage, then preventing pharmacists from working for other pharmacy employers to make up for the lost hours would be counterproductive and it would further exacerbate any "shortage".
As part of its inclusion and diversity strategy, the Royal Pharmaceutical Society (RPS) has launched a campaign to challenge barriers to working in pharmacy for those with disabilities.
A profession-wide survey on the subject conducted by the RPS, identified disability as the biggest barrier to working in pharmacy, highlighting the area of work to support pharmacists.
The campaign will focus on reducing barriers to enter the profession, developing more accessible working environments and encouraging employers to collect data on disability in the workplace.
The campaign, based on inputs from the RPS Ability Group volunteers with visible and non-visible disabilities, will run until the end of March.
Following recommendation of the RPS Ability Group, RPS has written to the General Pharmaceutical Council (GPhC) the Higher Education Occupational Practitioners (HEOPS) to update the guidance on standards of medical fitness for pharmacy students.
The Medicines and Healthcare products Regulatory Agency (MHRA) is doubling down on its efforts to combat online pharmacy frauds, emphasising innovation,
eradication of legacy systems, and cybersecurity in its updated technology roadmap.
The online sale of medicines and medical devices is a "growing phenomenon offering convenience, anonymity, and lower prices " for the public.
However the lack of robust cyber monitoring also "poses significant risks", as many online pharmacies are "unregulated, illegal, or fraudulent."
According to the MHRA's recent report highlighting the impact of artificial intelligence on the regulation of medical products, the strategic themes
of "fundamental to the successful deployment of AI" are essential for protecting consumers from fraudulent medical products.
Walgreens Boots Alliance has announced the launch of its new clinical trials business that aims to use patient data from its pharmacies to help drive up
recruitment in studies conducted by drugmakers.
With patient recruitment and enrollment remain key challenges in clinical trials, further exacerbated by the COVID-19 pandemic, the company said it can proactively
match diverse patient populations to trials across a range of disease areas based on race, gender, socioeconomic status and location with its patient reach and
access to an extensive foundation of pharmacy and patient-authorised clinical data.
The Boots owner also believes that by leveraging a tech-enabled approach to patient identification and creating a large registry of clinical trial participants,
the company will be able to reduce the time it takes to match eligible patients to clinical trials.
"Walgreens trusted community presence across the nation, combined with our enterprise-wide data and health capabilities, enables us to pioneer a comprehensive
solution that makes health options, including clinical trials, more accessible, convenient and equitable," said Ramita Tandon, chief clinical trials officer,
Walgreens.
Community Pharmacy England (CPE) has notified pharmacy teams that starting 1 August 2024, three Hormone Replacement Therapy (HRT) medicines will be
discontinued and will no longer be covered under the NHS HRT Prescription Prepayment Certificate (HRT PPC) scheme.
These are Bedol® 2mg tablets, Climanor® 5mg tablets and Clinorette® tablets.
Since Climanor® 5mg tablets have been discontinued, Medroxyprogesterone 5mg tablets will also be removed from the HRT PPC list, as this generic product is no
longer available as a licensed HRT medicine.
The CPE also noted that Provera® 5mg tablets, being an unlicensed HRT medicine, are not covered by the HRT PPC.
Pharmacy staff are advised to check the NHS Business Services Authority (NHSBSA) website for the most current list of HRT medicines covered by the HRT PPC.
The CPE has updated its HRT PPC medicines list to reflect these changes, which will also be updated in Part XVI of the August 2024 Drug Tariff.
Workforce issues, staff retention and capacity continues to be a big concern for the Local Pharmaceutical Committee as it discussed the topics at a recent meeting with the Pharmaceutical Services Negotiating Committee (PSNC).
The meeting, attended by delegates from 66 LPCs, focused on the current challenges faced by community pharmacies as well as the planning for the next year.
Around 64 per cent of delegates said workforce was the top challenge faced by pharmacy contractors, and suggested reducing the migration of pharmacists to Primary Care Networks (PCNs).
Other suggestions included - "improving the development opportunities available for pharmacists and their teams, and rebranding the profession to make community pharmacy a more attractive route for young graduates."
On the development of Integrated Care Systems (ICS), the majority of respondents were positive about their LPC's engagement in the new setting.
A community pharmacist, Viral Doshi was honoured with the British Citizen Award (BCA) on Thursday (26 January) at the Palace of Westminster for transforming
his community centre into vaccination hub during Covid-19 pandemic.
Viral was presented with his Medal of Honour by Liam Sargeant, Senior Company Communications Manager, from supporters P&G and TV presenter and Patron of the BCA,
Nick Knowles, who hosted the event.
At the height of the pandemic, Viral obtained approval to transform his community centre into a vaccination hub. Located in the heart of a multi-ethnic population,
with social deprivation, surrounded by wards experiencing high rates of Covid-19. His determination to increase uptake and reduce vaccination hesitancy, led to
80,000 vaccinations being administered, the overall highest vaccination uptake in North West London.
Viral is a passionate advocate for the role that GP practices and community pharmacies can play in supporting the health agenda. His objective, to provide better
choice and access for the community have been fully met and appreciated by patients. His initiatives led to a dramatic increase in the clinical skills, knowledge
and services offered by local community pharmacies around a variety of health topics. This enabled pharmacies to adopt a holistic health approach to working with
their communities.
The ongoing pharmacist workforce crisis has posed a significant risk to patients' access to care, medicines and advice - particularly affecting the elderly and vulnerable living in areas with health inequalities.
Many from the sector have raised concerns about this issue with the Company Chemists' Association (CCA) recently acknowledging the shortage of pharmacists or pharmacy technicians in the country to meet the needs of patients and the NHS.
The trade body representing almost 50 per cent of the community pharmacy sector said that pharmacy teams are exhausted after working tirelessly during the pandemic,
adding that Covid, Brexit and NHS reforms have exacerbated the shortage.
Covid and winter-related sickness absences are adding to the strain and with Brexit it has become difficult to attract overseas pharmacists to the UK.
Teva UK has alerted the Secretary of State for Health and Social Care to the problem posed by steep energy prices.
Teva's UK General Manager Kim Innes wrote to the minister seeking assurances that the distribution of medicines to patients will be safeguarded over what's likely
to be a difficult winter.
The problems posed by steep energy prices and the potential for power rationing is putting pharmacies under pressure from increased costs and the risk of losing power
supplies as a 'non-domestic' energy user, said the company.
Kim said: "In our letter to the Secretary of State we acknowledged that the government knows that medicines manufacture is strategically important and that it's a
vital component in maintaining patient health."
"But I wanted to make sure that the Secretary of State also realises the consequences of the energy crisis further down the supply chain - for example, the need for
a pharmacy to have a fridge switched on at all times for storing cold chain products."
The General Pharmaceutical Council (GPhC) has launched a consultation on whether people agree or disagree that its hearings should continue to be held remotely when it is fair and practical to do so.
The 12-week consultation - which ends on February 8 - seeks views on a proposed permanent change to the GPhC's procedural rules which will allow it to conduct
hearings and meetings by teleconference or videolink.
The pharmacy regulator is seeking changes to enable it to continue to hold some hearings remotely in the future following positive feedback from those taking part
in hearings during the Covid-19 pandemic which the GPhC held remotely by videolink.
"In cases where the GPhC investigates a concern about a pharmacist or pharmacy technician and decides there is evidence to show that their fitness to practise may
be impaired, the case may need to be referred for a hearing before a committee," GPhC said in a statement today (November 16).
Pharmacy contractors will no longer need to print and submit a paper copy of their completed FP34C declaration made through the Manage Your Service (MYS)
portal when submitting their paper prescription bundle to the NHS Business Services Authority (NHSBSA), said the Pharmaceutical Services Negotiating Committee (PSNC).
Instead, from August 2022 (for July 2022 prescriptions), NHSBSA will post out a paper Account Identifier Document along with the red separators and pharmacy address
labels each month.
"The Account Identifier Document should be placed alongside the paper prescription bundle before it is dispatched for payment to the relevant pricing division of
NHSBSA," said PSNC.
With the help of Account Identifier Document, NHSBSA will be able to easily identify the pharmacy that has submitted the prescription bundle, which will help to
speed up prescription processing.
"If the Account Identifier Document is lost or misplaced, contractors will still be able to download and print another copy from MYS. The July 2022 Drug Tariff
will be updated to reflect this change."
FreeStyle Libre 3 Sensors and Budesonide 500microgram orodispersible tablets sugar free have been included in the Drugs for which Discount is Not
Deducted (DND) list (Part II of the Drug Tariff) from January 2024, according to Community Pharmacy England (CPE).
Following applications made by CPE on behalf of pharmacy contractors, the Department of Health and Social Care (DHSC) agreed to give DND status to these
products to ensure that "pharmacies are not faced with dispensing these sensors at a loss."
Updated monthly by the DHSC, Part II of the Drug Tariff includes grouped and individual items.
Recently launched by Abbott Diabetes Care Ltd, FreeStyle Libre 3 Sensors have also been added to the Appliances section in Part IXA of the January 2024 Drug Tariff.
As the sensors can only be ordered by pharmacies directly from the manufacturer without any discount, CPE requested the DHSC to exempt this appliance from any
discount deduction.
Pharmacy wholesaler PHOENIX UK is investing over £13 million to build a new state-of-the-art distribution hub in Wakefield.
The 260,000 sq. ft facility is expected to be operational next year and will service community pharmacies, hospitals and dispensing doctors across the North East
of England and Yorkshire.
In a statement on Tuesday (July 5), PHOENIX UK said the completed hub will feature 22 dock level loading bays and seven access doors to enable the productive arrival
and distribution of medical products.
It will also be highly energy efficient, including the use of Solar PV on its roof. The car park will also offer 46 electric vehicle charging bays.
Speaking at an official opening event held on 30 June to mark the expansion of the company's distribution capabilities, group managing director of PHOENIX Steve
Anderson said: "Over the last few years, we have seen an outstanding growth in customer demand for our core services outpacing the market: Wakefield is a prime
example of how we are committed to investing in the future by expanding our UK-wide operational capabilities to offer all our customers across the country the
best possible service they need, want and deserve.
Paul Rees MBE has joined the National Pharmacy Association (NPA) today (27 November) as its new Chief Executive.
Current NPA Chief Executive Mark Lyonette, who is retiring, will remain at the NPA for some weeks in order to ensure a smooth handover.
Previously, Paul has worked as the Chief Executive of the Royal College of Psychiatrists for the seven years.
On joining NPA, Paul said: "It is a great privilege and honour to take up the position of NPA Chief Executive. The association is the voice of independent
community pharmacy and is core to the sector's future success in England, Scotland, Wales and Northern Ireland.
"I am delighted that the NPA has placed its trust in me and I intend to deliver for NPA members, for the sector and for society at large, which relies on there
being a vibrant community pharmacy network in villages, towns and cities across the four nations of the UK."
When Paul's appointment was first announced in September, NPA Chair Nick Kaye said that they identified him as an "excellent fit for our organisation" after a
rigorous recruitment process, and also thanked Mark for his "great work as chief exec since 2018."
Indian authorities have cancelled or suspended licences of some domestic drug companies as part of action taken against 76 pharmaceutical firms this month for
selling adulterated or fake products, a government source said on Thursday.
India is known as the 'pharmacy of the world' and its pharmaceuticals exports have more than doubled over the past decade to $24.5 billion in 2021-22.
But that image has been dented by the death of at least 70 children in Gambia and 19 children in Uzbekistan in Uzbekistan last year linked to drugs made by
India-based pharmaceutical companies.
Health Minister Mansukh Mandaviya confirmed a crackdown but did not give details of companies against which action had been taken.
"There are more than 10,500 pharma companies in the country. Companies who make spurious medicine will not be spared," Mandaviya told reporters at an event.
Licences of some Indian drug companies have been cancelled, some were suspended while others have been put on notice during the past 15 days, the source, who had
direct knowledge of the matter, told Reuters news agency.
The National Pharmacy Association (NPA) Board has elected 14 Board members on Friday (30 March) that will govern the association for next two years.
Four new Board members have been elected while five previous members left the Board after serving their terms. The period April 2023 to March 2025 will see the
completion of the transition to the new Board structure.
The Board will meet again on Monday (24 April) to elect the Chair and other appointments.
Gareth Jones, Returning Officer for the NPA Board elections, said: "The NPA has undertaken a process of significant modernisation of organisational governance over
the past years. Key elements of this process include adopting modern new Articles of Association, reforming the structure of the Board and introducing term limits.
The process of electing the Board has also been changed so that half of the Board will be up for election every two years - which supports continuity and reduces the
risk of a loss of organisational memory."
"Recognising that the Board would already be losing a lot of organisational memory in 2023 with five members of Board standing down, the Board determined that three
individuals should be co-opted onto the new Board as the process of transformation continues. In March 2025, anyone that has served 12 years or more will be required
to stand down."
The Royal Pharmaceutical Society (RPS) has updated the Professional Standards for Homecare Services to ensure high quality care for patients receiving
medicines and associated services in the comfort of their own homes.
Originally published in 2013, these standards provide a comprehensive framework to support teams involved in planning, commissioning, and delivering homecare
services.
The RPS said that these standards were updated to ensure that they align with the needs and expectations of recipients of homecare services, as well as
commissioners and providers.
Changes were made based on responses received through a consultation process, which was participated by representatives from the National Homecare Medicines
Committee, the Association of Pharmacy Technicians, the Pharmacy Forum of Northern Ireland, and the Royal College of Nursing.
Merseyside Police have appealed for information from the public following the theft of "a large quantity" of medication from a pharmacy in West Derby this week.
As per the police report, the burglary occurred in the early hours of Monday, 12 February, at the pharmacy situated on Deysbrook Lane. Authorities were informed
at around 9:15 am.
Based on the CCTV footage they have recovered, the Merseyside Police revealed that a man entered the pharmacy at around 1.20 am on 12 February and stole a large
quantity of medication, including diazepam, codeine, co-codamol, pregabalin, zopiclone.
These are prescription-only drugs that could cause "serious harm" if a significant amount is taken, the report said.
The suspect, described as a white man of slim build, was wearing a grey coloured tracksuit and glasses, according to the police.
In its latest style guide for digital health writing, the NHS advises bloggers and writers to avoid using the word 'chemist' when referring to a 'pharmacy' as users are more likely to look for the latter.
Likewise, the content guide titled 'A to Z of NHS health writing' encourages writers to use 'ethnic minorities' rather than the more commonly used abbreviated forms
such as 'BAME' or 'BME'.
"Use a capital letter when you're writing about ethnicity or when you're asking users for their ethnic group," it advises, and therefore recommends writing 'Black,
Asian, African, Black British or Caribbean' or 'people from a White British background'.
In a further chapter on 'Ethnicity, Religion and Nationality,' it notes that a writer should "only refer to people's ethnic heritage or religion if it's relevant to the content."
Likewise, when talking about skin colour, the style guide asks to use terms that are easy to understand including brown and black skin. "We do not refer to brown or black skin as 'dark' or 'darker'."
It advises not to describe people as mentally ill but use phrases such as 'mental health condition' or 'mental health problems'.